Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK-Reference-Cited by-同舟云学术

Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK

Published:2016-06 Issue: Volume: Page:243
ISSN:1178-6981
Container-title:ClinicoEconomics and Outcomes Research
language:en
Short-container-title:CEOR

Author:

Eklund Oskar,Afzal Faraz,Flavin Jason,Ternouth Andrew,Ojanguren Maria Eugenia,Crespo Carlos,Baldwin Mike,Borgström Fredrik

Publisher

Informa UK Limited

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review;Tuberculosis and Respiratory Diseases;2024-07-01

2. Estimating the Health and Economic Impact of Improved Management in Prevalent Chronic Obstructive Pulmonary Disease Populations in England, Germany, Canada, and Japan: A Modelling Study;International Journal of Chronic Obstructive Pulmonary Disease;2023-09

3. Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?;Expert Opinion on Pharmacotherapy;2021-01-13

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

;International Journal of Chronic Obstructive Pulmonary Disease;2020-04

5. Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective;Cost Effectiveness and Resource Allocation;2018-05-10